恒瑞医药(600276.SH)：SHR-1139注射液获得药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of SHR-1139 injection, a self-developed biological product aimed at treating ulcerative colitis through mechanisms that inhibit inflammation and maintain epithelial barrier [1] Group 1 - The company’s subsidiary, Guangdong Hengrui Medicine Co., Ltd., is responsible for the clinical trial of SHR-1139 injection [1] - SHR-1139 injection is expected to enhance treatment efficacy for ulcerative colitis by targeting inflammation and epithelial barrier maintenance [1]